About US
Contact us
-
Moderna strikes deal worth up to $1B to develop, produce mRNA drugs in China: reportsDespite political tensions between Washington and Beijing, foreign pharmaceutical investments are progressingin China. Now, as the commerce minister of the world’s second largest economy signals the2023/7/3
-
Samsung Biologics, Pfizer expand biosimilar production partnership with pair of deals worth $897MWith Pfizer set this month to launch its biosimilar version of AbbVie’s mega-blockbuster Humira, the company has expanded its partnership with Samsung Biologics, which will produce biosimilars for th2023/7/3
-
SK bioscience inks deal to support vaccine manufacturing in ThailandSK biosciencesigned a memorandum of understandingwith Thailand’s Government Pharmaceutical Organization to help develop the country’s vaccine manufacturing sector, with the partners aiming to turn th2023/6/27
-
Antibody aficionado Abcam explores strategic alternatives—including a potential saleHalf a decade after Abcam quit its 270 million pound sterling pursuit of Horizon Discovery, the British antibody research expert has potentially found itself on the opposite end of the dealmaking tab2023/6/27
-
With approval supplement on deck, Reata dives into launch of its first commercial product SkyclarysWith a spring approval in hand, Reata Pharmaceuticals has been waiting patiently to launch its first commercial product, Skyclarys. Now,after an impurity problem stalled the rare disease med’s debut,2023/6/22
-
Andelyn Biosciences debuts cell and gene manufacturing headquarters in OhioAndelyn Biosciences, a cell and gene therapy CDMO,unveileda new manufacturing headquarters in Ohio, more than tripling its production footprint. The Andelyn Corporate Center in Columbus, Ohio, add2023/6/22
-
Lupin wins approval for first US generic of Boehringer Ingelheim's COPD blockbuster SpirivaLupin of India has become the first company toscoreapproval in the U.S. for its generic version of Boehringer Ingelheim’s blockbuster COPD treatment Spiriva HandiHaler. The2023/6/20
-
As Adderall shortages persist, Takeda's rival Vyvanse is now in short supplyMany months into the U.S. shortage of attention-deficit/hyperactivity disorder (ADHD) drug Adderall and its generics, a rival medicine from Takeda is now in short supply. In astatementon the Vyvan2023/6/20
-
Johnson & Johnson inks another Stelara patent settlement, this time with Alvotech and TevaAnother biosimilar product copying Johnson & Johnson’s top-selling drug Stelara may enter the U.S. market without a patent infringement challenge by early 2025 thanks to a new settlement. J&am2023/6/16
-
After Albireo buyout, Ipsen's Bylvay picks up new FDA-approved useAfter Ipsenmade a splashat this year's J.P. Morgan Healthcare Conference by scooping up liver disease specialist Albireo Pharma, the centerpiece of the buyout, Bylvay, has won a coveted label expansi2023/6/16